Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Neil Ashley is active.

Publication


Featured researches published by Neil Ashley.


Biochemical and Biophysical Research Communications | 2009

Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs.

Neil Ashley; Joanna Poulton

The anthracyclines, such as doxorubicin (DXR), are potent anti-cancer drugs but they are limited by their clinical toxicity. The mechanisms involved remain poorly understood partly because of the difficulty in determining sub-cellular drug localisation. Using a novel method utilising the fluorescent DNA dye PicoGreen, we found that anthracyclines intercalated not only into nuclear DNA but also mitochondrial DNA (mtDNA). Intercalation of mtDNA by anthracyclines may thus contribute to the marked mitochondrial toxicity associated with these drugs. By contrast, ethidium bromide intercalated exclusively into mtDNA, without interacting with nuclear DNA, thereby explaining why mtDNA is the main target for ethidium. By exploiting PicoGreen quenching we also developed a novel assay for quantification of mtDNA levels by flow-cytometry, an approach which should be useful for studies of mitochondrial dysfunction. In summary our PicoGreen assay should be useful to study drug/DNA interactions within live cells, and facilitate therapeutic drug monitoring and kinetic studies in cancer patients.


Cancer Research | 2013

Stem Cell Differentiation and Lumen Formation in Colorectal Cancer Cell Lines and Primary Tumors

Neil Ashley; Trevor M. Yeung; Walter F. Bodmer

Single cancer stem-like cells (CSC) from colorectal cancers can be functionally identified by their ability to form large lumen-containing colonies in three-dimensional Matrigel cultures. These colonies contain the three types of differentiated colorectal epithelial cells, and single cells obtained from them can reproduce themselves and form tumors efficiently in immunodeficient mice. In this study, we show how hypoxia affects these CSC-derived lumens to control differentiation of stem-like cells and enterocytes via the homeobox gene CDX1. Lumens were identified by F-actin staining and they expressed many characteristics associated with normal differentiated intestinal epithelium, including brush border enzymes, polarization, and tight junctions. RNA interference-mediated silencing of CDX1 reduced lumen formation. Inhibitory effects of hypoxia on lumen formation and stem cell differentiation, including suppression of CDX1 expression, could be mimicked by inhibiting prolyl-hydroxylases that activate HIF1, suggesting that HIF1 is a critical mediator of the effects of hypoxia in this setting. Cell line-derived lumens were phenotypically indistinguishable from colorectal tumor glandular structures used by pathologists to grade tumor differentiation. Parallel results to those obtained with established cell lines were seen with primary cultures from fresh tumors. This in vitro approach to functional characterization of CSCs and their differentiation offers a valid model to study colorectal tumor differentiation and differentiation of colorectal CSCs, with additional uses to enable high-throughput screening for novel anticancer compounds.


Proceedings of the National Academy of Sciences of the United States of America | 2016

Myofibroblasts are distinguished from activated skin fibroblasts by the expression of AOC3 and other associated markers

Lin-ting Hsia; Neil Ashley; Djamila Ouaret; Lai Mun Wang; Jennifer L. Wilding; Walter F. Bodmer

Significance Myofibroblasts surround the epithelial cells of the crypts that form the surface of the gut. They play an important role in controlling the normal epithelium and influence the development of colorectal and other epithelial cancers. The definition of myofibroblasts previously depended almost entirely on the expression of smooth muscle actin. We identified the surface enzyme AOC3 (amine oxidase, copper containing 3) as a new marker of myofibroblasts and as a result have discovered additional highly distinctive markers for myofibroblasts, including the transcription factor NKX2-3. The discovery of these new markers should greatly enhance the proper definition of myofibroblasts and related cell types and thus should contribute to the improved treatment of the many diseases, including cancer, that involve these cell types. Pericryptal myofibroblasts in the colon and rectum play an important role in regulating the normal colorectal stem cell niche and facilitating tumor progression. Myofibroblasts previously have been distinguished from normal fibroblasts mostly by the expression of α smooth muscle actin (αSMA). We now have identified AOC3 (amine oxidase, copper containing 3), a surface monoamine oxidase, as a new marker of myofibroblasts by showing that it is the target protein of the myofibroblast-reacting mAb PR2D3. The normal and tumor tissue distribution and the cell line reactivity of AOC3 match that expected for myofibroblasts. We have shown that the surface expression of AOC3 is sensitive to digestion by trypsin and collagenase and that anti-AOC3 antibodies can be used for FACS sorting of myofibroblasts obtained by nonenzymatic procedures. Whole-genome microarray mRNA-expression profiles of myofibroblasts and skin fibroblasts revealed four additional genes that are significantly differentially expressed in these two cell types: NKX2-3 and LRRC17 in myofibroblasts and SHOX2 and TBX5 in skin fibroblasts. TGFβ substantially down-regulated AOC3 expression in myofibroblasts but in skin fibroblasts it dramatically increased the expression of αSMA. A knockdown of NKX2-3 in myofibroblasts caused a decrease of myofibroblast-related gene expression and increased expression of the fibroblast-associated gene SHOX2, suggesting that NKX2-3 is a key mediator for maintaining myofibroblast characteristics. Our results show that colorectal myofibroblasts, as defined by the expression of AOC3, NKX2-3, and other markers, are a distinctly different cell type from TGFβ-activated fibroblasts.


The Journal of Pathology | 2014

Rapidly derived colorectal cancer cultures recapitulate parental cancer characteristics and enable personalized therapeutic assays.

Neil Ashley; Matthew F. Jones; Djamila Ouaret; Jenny Wilding; Walter F. Bodmer

We have developed a simple procedure for deriving pure cultures of growing cancer cells from colorectal cancers, including material refrigerated overnight, for pathological characterization and cytotoxicity assays. Forty‐six cancers were processed and cultures set up under varying culture conditions. Use of a Rho kinase (ROCK1) inhibitor markedly increased culture survival, resulting in 80% of samples growing in culture for at least 1 month and beyond. Overnight refrigeration of samples before culture initiation had little effect on success rates, paving the way for cultures to be established for samples collected over wide geographical areas, such as those for clinical trials. Primary cultures demonstrated good correlation for differentiation markers compared to parent cancers, and were highly dynamic in 3D culture. In Matrigel, many colonies formed central lumens, indicating the presence of stem‐like cells. Viable colonies in these cultures recapitulated the in vivo generation of carcinoembryonic antigen (CEA)‐positive necrotic/apoptotic debris, much of which was derived from abnormal vacuolated dynamic ‘bubble cells’ that have not previously been described. Although bubble cells morphologically resembled signet ring cells, a rare cancer subtype, immunostaining suggested that they were most likely derived from terminally differentiated enterocytes. Micro‐assays showed that drug toxicity could be measured in these cultures within hours and with sensitivity down to a few hundred cells. Primary cultures derived by our method provide valid in vitro avatars for studying the pathology of cancers in vitro and are amenable to pre‐clinical drug testing, paving the way for personalized cancer treatment. Copyright


Lab on a Chip | 2018

Sequencing of human genomes extracted from single cancer cells isolated in a valveless microfluidic device.

Rodolphe Marie; Marie Pødenphant; Kamila Koprowska; Loïc Baerlocher; Roland C. M. Vulders; Jennifer L. Wilding; Neil Ashley; Simon J. McGowan; Dianne van Strijp; Freek Van Hemert; Tom Olesen; Niels Agersnap; Brian Bilenberg; Céline Sabatel; Julien Schira; Anders Kristensen; Walter F. Bodmer; Pieter J. Van der Zaag; Kalim U. Mir

Sequencing the genomes of individual cells enables the direct determination of genetic heterogeneity amongst cells within a population. We have developed an injection-moulded valveless microfluidic device in which single cells from colorectal cancer derived cell lines (LS174T, LS180 and RKO) and fresh colorectal tumors have been individually trapped, their genomes extracted and prepared for sequencing using multiple displacement amplification (MDA). Ninety nine percent of the DNA sequences obtained mapped to a reference human genome, indicating that there was effectively no contamination of these samples from non-human sources. In addition, most of the reads are correctly paired, with a low percentage of singletons (0.17 ± 0.06%) and we obtain genome coverages approaching 90%. To achieve this high quality, our device design and process shows that amplification can be conducted in microliter volumes as long as the lysis is in sub-nanoliter volumes. Our data thus demonstrates that high quality whole genome sequencing of single cells can be achieved using a relatively simple, inexpensive and scalable device. Detection of genetic heterogeneity at the single cell level, as we have demonstrated for freshly obtained single cancer cells, could soon become available as a clinical tool to precisely match treatment with the properties of a patients own tumor.


Cell | 2018

Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel Disease

James Kinchen; Hannah H. Chen; Kaushal Parikh; Agne Antanaviciute; Marta Jagielowicz; David Fawkner-Corbett; Neil Ashley; Laura Cubitt; Esther Mellado-Gomez; Moustafa Attar; Eshita Sharma; Quin F. Wills; Rory Bowden; Felix Clemens Richter; David Ahern; Kamal D. Puri; Jill Henault; Francois Gervais; Hashem Koohy; Alison Simmons

Summary Intestinal mesenchymal cells play essential roles in epithelial homeostasis, matrix remodeling, immunity, and inflammation. But the extent of heterogeneity within the colonic mesenchyme in these processes remains unknown. Using unbiased single-cell profiling of over 16,500 colonic mesenchymal cells, we reveal four subsets of fibroblasts expressing divergent transcriptional regulators and functional pathways, in addition to pericytes and myofibroblasts. We identified a niche population located in proximity to epithelial crypts expressing SOX6, F3 (CD142), and WNT genes essential for colonic epithelial stem cell function. In colitis, we observed dysregulation of this niche and emergence of an activated mesenchymal population. This subset expressed TNF superfamily member 14 (TNFSF14), fibroblastic reticular cell-associated genes, IL-33, and Lysyl oxidases. Further, it induced factors that impaired epithelial proliferation and maturation and contributed to oxidative stress and disease severity in vivo. Our work defines how the colonic mesenchyme remodels to fuel inflammation and barrier dysfunction in IBD.


Human Molecular Genetics | 2004

Twinkle helicase is essential for mtDNA maintenance and regulates mtDNA copy number

Henna Tyynismaa; Hiroshi Sembongi; Monika Bokori-Brown; Caroline Granycome; Neil Ashley; Joanna Poulton; Anu Jalanko; Johannes N. Spelbrink; Ian J. Holt; Anu Suomalainen


Experimental Cell Research | 2005

Detection of mitochondrial DNA depletion in living human cells using PicoGreen staining

Neil Ashley; Dot Harris; Joanna Poulton


Human Molecular Genetics | 2008

Depletion of mitochondrial DNA in fibroblast cultures from patients with POLG1 mutations is a consequence of catalytic mutations

Neil Ashley; A O'Rourke; C Smith; Susan Adams; Vasantha Gowda; Massimo Zeviani; Garry K. Brown; Carl Fratter; Joanna Poulton


Mitochondrion | 2007

Liver mtDNA content increases during development: a comparison of methods and the importance of age- and tissue-specific controls for the diagnosis of mtDNA depletion.

Karl Morten; Neil Ashley; Frits A. Wijburg; Nedim Hadzic; Jeremy R. Parr; Sandeep Jayawant; Susan Adams; Laurence A. Bindoff; Henk D. Bakker; Giorgina Mieli-Vergani; Massimo Zeviani; Joanna Poulton

Collaboration


Dive into the Neil Ashley's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

An Williams

Northampton General Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Massimo Zeviani

MRC Mitochondrial Biology Unit

View shared research outputs
Top Co-Authors

Avatar

Susan Adams

John Radcliffe Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge